GladmanDDUrowitzMBGoldsmithCH, et al.The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum1997; 40: 809–813.
2.
RahmanPGladmanDDUrowitzMBHallettDTamLS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus2001; 10: 93–96.
3.
MaddisonPFarewellVIsenbergD, et al.The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol2002; 29: 913–917.
4.
RavelliADuarte-SalazarCBurattiS, et al.Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum2003; 49: 501–507.
5.
AlarconGSMcGwinJrGBartolucciAA, et al.Systemic lupus erythematosus in three ethnic groups IX. Differences in damage accrual. Arthritis Rheum2001; 44: 2797–2806.
6.
Ugarte-GilMFWojdylaDPons-EstelGJ, et al.Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Ann Rheum Dis2017; 76: 2071–2074.
7.
FesslerBJAlarconGSMcGwinGJr, et al.Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum2005; 52: 1473–1480.
8.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
9.
Ruiz IrastorzaGEgurbideMVUgaldeJAguirreC. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med2004; 164: 77–82.
10.
ContiFCeccarelliFPerriconeC, et al.The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. Lupus2016; 25: 719–721.
11.
TaraborelliMLevenbergerLLazzaroniMG, et al.The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. Lupus2016; 25: 1365–1368.
12.
TaraborelliMCavazzanaIMartinazziN, et al.Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. Lupus2017; 26: 1197–1204.
13.
Pinto-Peñaranda LuisFMuñoz-GrajalesCEcheverri GarciaAF, et al.Antiphospholipid antibodies, steroid dose, arterial hypertension, relapses, and late-onset predict organ damage in a population of Colombian patients with systemic lupus erythematosus. Clin Rheumatol2018; 37: 949–954.
14.
CerveraRSerranoRPons-EstelGJ, et al.Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis2015; 74: 1011–1018.
15.
AmigoMCGoycochea-RoblesMVEspinosa-CuervoG, et al.Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus2015; 24: 927–934.
16.
AshersonRACerveraRDe GrootPG, et al.Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus2003; 12: 530–534.
17.
ErkanDAshersonRAEspinosaG, et al.Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis2003; 62: 530–533.
